FDA Expands Drug Repurposing to Speed Up Access to New Treatments
The FDA announced that it is collecting information from researchers, clinicians, patients, and industry stakeholders to identify approved drugs that may offer additional therapeutic benefits beyond their original use. According to the agency, drug repurposing can accelerate treatment availability because developers already understand many aspects of the drug’s safety profile and clinical behavior.
The initiative mainly targets disease areas with major unmet medical needs. These areas include metabolic disorders, neurodegenerative diseases, women’s and men’s health conditions, substance use disorders, and rare diseases. In addition, the FDA wants stakeholders to highlight drug candidates that already show promising clinical or scientific evidence.
FDA Turns to AI Evidence for Drug Repurposing Decisions
The agency stated that it is interested in several categories of evidence that could support future drug repurposing efforts. These include approved drugs with sufficient clinical evidence for a potential new use, products supported by observational studies or case reports, and candidates identified through emerging technologies such as artificial intelligence and machine learning.
As a result, the announcement highlights the growing role of AI-driven analysis in pharmaceutical research and regulatory science. The FDA specifically referenced preliminary preclinical findings generated through AI and machine learning tools, signaling increasing regulatory attention toward digital evidence generation in drug development workflows.
FDA Signals Major Shift in Drug Repurposing Strategy
FDA Commissioner Marty Makary stated that many patients still lack effective treatment options despite the availability of promising scientific data. Therefore, the agency believes drug repurposing could help deliver faster access to therapies by making better use of existing evidence.
Furthermore, the FDA explained that this initiative forms part of a broader effort to modernize drug labeling and keep regulatory information scientifically updated. The agency also linked the program to previous regulatory frameworks and modernization initiatives, including the MODERN Labeling Act and Project Renewal.
FDA and NIH Expand Drug Repurposing Collaboration
The FDA confirmed that it plans to strengthen collaboration with federal partners, including the National Institutes of Health and the Centers for Medicare and Medicaid Services. According to the agency, public feedback will help refine future strategies for evaluating and facilitating additional drug repurposing opportunities.
In addition, the FDA referenced the 2025 “Make Our Children Healthy Again” strategy report, which encouraged closer collaboration between federal agencies to support repurposed drugs for chronic diseases and improve approval pathways through collaborative clinical trial designs.
AI Accelerates Drug Repurposing in Regulatory Science
The latest FDA initiative reflects a broader transformation across the pharmaceutical industry. Regulatory agencies increasingly explore AI-supported evidence generation, digital research models, and accelerated development pathways to reduce delays in treatment access.
At the same time, the growing use of AI and machine learning in regulated environments continues to raise important discussions around validation, data reliability, and regulatory acceptance standards. Consequently, the FDA’s latest move may influence future approaches to drug development, evidence evaluation, and pharmaceutical compliance strategies worldwide.
As FDA moves toward AI-driven evidence and updated regulatory pathways, ensuring robust system validation becomes essential for compliance and data integrity.
Discover how we support pharmaceutical teams with Qualification and Validation for GMP-Regulated Systems to build inspection-ready, compliant digital environments.
Source: FDA